Thorsten Zenz

32.1k total citations · 1 hit paper
166 papers, 6.5k citations indexed

About

Thorsten Zenz is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Thorsten Zenz has authored 166 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Genetics, 62 papers in Pathology and Forensic Medicine and 56 papers in Immunology. Recurrent topics in Thorsten Zenz's work include Chronic Lymphocytic Leukemia Research (126 papers), Lymphoma Diagnosis and Treatment (59 papers) and Immunodeficiency and Autoimmune Disorders (30 papers). Thorsten Zenz is often cited by papers focused on Chronic Lymphocytic Leukemia Research (126 papers), Lymphoma Diagnosis and Treatment (59 papers) and Immunodeficiency and Autoimmune Disorders (30 papers). Thorsten Zenz collaborates with scholars based in Germany, Switzerland and United States. Thorsten Zenz's co-authors include Stephan Stilgenbauer, Hartmut Döhner, Daniel Mertens, Andreas Bühler, Dirk Winkler, Michael Hallek, Sascha Dietrich, Wolfgang Huber, Ralf Küppers and Britta Velten and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Thorsten Zenz

160 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multi‐Omics Factor Analysis—a framework for unsupervised integration of multi‐omics data sets

2018 664 citations Ricard Argelaguet, Britta Velten et al. Molecular Systems Biology profile →

Peers

Countries citing papers authored by Thorsten Zenz

Since Specialization

Citations

This map shows the geographic impact of Thorsten Zenz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thorsten Zenz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thorsten Zenz more than expected).

Fields of papers citing papers by Thorsten Zenz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thorsten Zenz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thorsten Zenz. The network helps show where Thorsten Zenz may publish in the future.

Co-authorship network of co-authors of Thorsten Zenz

This figure shows the co-authorship network connecting the top 25 collaborators of Thorsten Zenz. A scholar is included among the top collaborators of Thorsten Zenz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thorsten Zenz. Thorsten Zenz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prophylactic Tocilizumab prior to infusion of CD19 CAR T-cells reduces therapy-related complications in older lymphoma patients 2025 ·Annals of Hematology ·(unknown), (unknown), (unknown), (unknown), (unknown), Markus G. Manz, (unknown), Dominik Schneidawind, (unknown), Thorsten Zenz, (unknown)	1
2	Fluctuating DNA methylation tracks cancer evolution at clinical scale 2025 ·Nature ·(unknown), Martí Duran‐Ferrer, (unknown), Diego Mallo, Ferran Nadeu, Jacob Househam, Neus Villamor, (unknown), Simon Heath, Emanuele Raineri, (unknown), Jessica Nordlund, Thorsten Zenz, (unknown), Elı́as Campo, Armando López‐Guillermo, Jude Fitzgibbon, C. Barnes, Darryl Shibata, José I. Martı́n-Subero, Trevor A. Graham	2
3	Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial 2025 ·Blood ·Adalgisa Condoluci, Ilaria Romano, Daniel Dietrich, (unknown), Georg Stüssi, (unknown), Nathan Cantoni, Richard Cathomas, Ulrich Mey, (unknown), Thorsten Zenz, Michael Gregor, Dominik Heim, Martin Andres, Rudolf Benz, Davide Rossi	2
4	Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes 2024 ·Blood Advances ·(unknown), Élise Chapiro, Ferran Nadeu, Thorsten Zenz, Sı́lvia Beà, (unknown), Marta Aymerich, Marı́a Rozman, Damien Roos‐Weil, Olivier Bernard, Santos A. Susín, Helen Parker, Renata Walewska, Christopher C. Oakes, Jonathan C. Strefford, Elı́as Campo, Estella Matutes, Martí Duran‐Ferrer, Florence Nguyen‐Khac, José I. Martı́n-Subero	1
5	Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies 2023 ·Blood Advances ·Sophie A. Herbst, Vladislav Kim, Tobias Roider, (unknown), Peter‐Martin Bruch, Nora Liebers, Carolin Kolb, (unknown), Junyan Lu, Peter Dreger, Carsten Müller‐Tidow, Thorsten Zenz, Wolfgang Huber, Sascha Dietrich	7
6	A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression 2022 ·Blood Advances ·Pau Abrisqueta, Daniel Medina, Guillermo Villacampa, Junyan Lu, Miguel Alcoceba, (unknown), (unknown), Bárbara Tazón‐Vega, Gloria Iacoboni, Sabela Bobillo, Ana Marín‐Niebla, Marcos González, Thorsten Zenz, Marta Crespo, Francesc Bosch	2
7	Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape 2022 ·Nature Communications ·(unknown), Alba Maiqués-Díaz, (unknown), Elena Hartmann, Johannes Bloehdorn, A. P. Moore, (unknown), Junyan Lu, Valar Nila Roamio Franklin, (unknown), (unknown), Andreas Rosenwald, Stephan Stilgenbauer, Thorsten Zenz, Irina Mohorianu, Clive S. D’Santos, Silvia Deaglio, Daniel J. Hodson, José I. Martı́n-Subero, Ingo Ringshausen	19
8	Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL 2022 ·Molecular Systems Biology ·Peter‐Martin Bruch, (unknown), Carolin Kolb, Sophie A. Herbst, (unknown), Tobias Roider, Junyan Lu, (unknown), Lena Wagner, (unknown), Ivan Berest, Mark Kriegsmann, Katharina Kriegsmann, Christiane Zgorzelski, Peter Dreger, Judith B. Zaugg, Carsten Müller‐Tidow, Thorsten Zenz, Wolfgang Huber, Sascha Dietrich	10
9	The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision 2021 ·Leukemia ·Friederike Herbst, (unknown), (unknown), Peer Wünsche, Alexander Arthur Wurm, (unknown), (unknown), (unknown), Agnes Hotz‐Wagenblatt, Oksana Zavidij, Anna Paruzynski, Junyan Lu, Christof von Kalle, Thorsten Zenz, Christoph Klein, Manfred Schmidt, Claudia R. Ball, Hanno Glimm	11
10	Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia 2021 ·Nature Communications ·Veronika Ecker, (unknown), (unknown), (unknown), (unknown), Thomas Engleitner, Ingo Ringshausen, (unknown), Manfred Jücker, S. Wänninger, Thorsten Zenz, Clemens‐Martin Wendtner, Katrin Manske, Katja Steiger, Roland Rad, Markus Müschen, Jürgen Ruland, Maike Buchner	50
11	Identification of two DNA methylation subtypes of Waldenström's macroglobulinemia with plasma and memory B cell features 2020 ·Blood ·Damien Roos‐Weil, Brian Giacopelli, Marine Armand, Véronique Della-Valle, Hussein Ghamlouch, (unknown), Marlen Metzner, Junyan Lu, Magali Le Garff‐Tavernier, Véronique Leblond, Paresh Vyas, Thorsten Zenz, Florence Nguyen‐Khac, Olivier Bernard, Christopher C. Oakes	6
12	Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia 2020 ·The Journal of Experimental Medicine ·(unknown), Veronika Ecker, (unknown), Martina Braun, Wilko Weichert, Stephan Macher-Göppinger, (unknown), (unknown), Thorsten Zenz, Maike Buchner, Jürgen Ruland	15
13	Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma 2018 ·Scientific Reports ·(unknown), (unknown), Kwang Seok Lee, Jennifer Hüllein, Marina Lukas, Leopold Sellner, Tatjana Walther, Lena Wagner, Małgorzata Oleś, Benedikt Brors, Wolfgang Huber, Thorsten Zenz	21
14	Multi‐Omics Factor Analysis—a framework for unsupervised integration of multi‐omics data sets breakdown → 2018 ·Molecular Systems Biology ·Ricard Argelaguet, Britta Velten, Damien Arnol, Sascha Dietrich, Thorsten Zenz, John C. Marioni, Florian Buettner, Wolfgang Huber, Oliver Stegle	664
15	MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia 2017 ·British Journal of Haematology ·Bian Wu, Mikołaj Słabicki, Leopold Sellner, Sascha Dietrich, Xiyang Liu, Alexander Jethwa, Jennifer Hüllein, Tatjana Walther, Lena Wagner, Zhiqin Huang, Marc Zapatka, Thorsten Zenz	27
16	Targeting the BRAF V600E Mutation in Multiple Myeloma 2013 ·Cancer Discovery ·Mindaugas Andrulis, Nicola Lehners, David Capper, Roland Penzel, Christoph Heining, (unknown), Thorsten Zenz, Andreas von Deimling, Peter Schirmacher, Anthony D. Ho, Hartmut Goldschmidt, Kai Neben, Marc S. Raab	171
17	Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia 2013 ·Cancer Discovery ·Christopher C. Oakes, Rainer Claus, Lei Gu, Yassen Assenov, Jennifer Hüllein, Manuela Zucknick, Matthias Bieg, David Brocks, Olga Bogatyrova, Christopher R. Schmidt, Laura Z. Rassenti, Thomas J. Kipps, Daniel Mertens, Peter Lichter, Hartmut Döhner, Stephan Stilgenbauer, John C. Byrd, Thorsten Zenz, Christoph Plass	110
18	High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial 2013 ·Blood ·Johannes Bloehdorn, Martin Sill, Christian Langer, Axel Benner, (unknown), Thorsten Zenz, Andreas Bühler, Raymonde Busch, Peter Dreger, Ulrich Jäger, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer	1
19	P53 and microRNAs in chronic lymphocytic leukemia 2011 ·Johannes Bloehdorn, Christian Langer, Hartmut Döhner, Thorsten Zenz, Stephan Stilgenbauer	0
20	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia 2009 ·Cancer Research ·(unknown), Thorsten Zenz, Andrea Schnaiter, Daniel Mertens, Dirk Winkler, Hartmut Döhner, Klaus‐Michael Debatin, Stephan Stilgenbauer, Simone Fulda	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact